Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal disease

- PMLiVE

BioNTech boosts COVID-19 vaccine capacity and aims to deliver 2 billion doses in 2021

Company will also publish data on vaccine's efficacy against new variants soon

- PMLiVE

Pfizer/BioNTech vaccine shown to be effective against new COVID-19 variants

Vaccine tested against variants discovered in the UK and South Africa

- PMLiVE

Moderna wins EU authorisation for COVID-19 vaccine

EU Commission approval comes on the same day as positive CHMP opinion

- PMLiVE

Pfizer introduces new logo in a ‘shift from commerce to science’

First major rebranding in 70 years for pharma giant

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

- PMLiVE

WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule

Recommendations made by the WHO's Strategic Advisory Group of Experts on Immunization

- PMLiVE

Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients

Only those trial participants who are currently eligible under the EUA will be offered the vaccine

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

Roche Basel Switzerland

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Treatment can be administered as an injection instead of an intravenous infusion

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

UPDATED: EU authorises Pfizer/BioNTech’s COVID-19 vaccine

Authorisation closely follows CHMP recommendation

- PMLiVE

EU authorises Aimmune’s peanut allergy treatment Palforzia

Approval in the EU comes nine months after US authorisation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links